Broekhuizen Henk, IJzerman Maarten J, Hauber A Brett, Groothuis-Oudshoorn Catharina G M
Department of Health Technology and Services Research, MIRA institute, University of Twente, PO Box 217, 7500 AE, Enschede, The Netherlands.
RTI Health Solutions, Research Triangle Park, NC, USA.
Pharmacoeconomics. 2017 Mar;35(3):259-269. doi: 10.1007/s40273-016-0467-z.
The need for patient engagement has been recognized by regulatory agencies, but there is no consensus about how to operationalize this. One approach is the formal elicitation and use of patient preferences for weighing clinical outcomes. The aim of this study was to demonstrate how patient preferences can be used to weigh clinical outcomes when both preferences and clinical outcomes are uncertain by applying a probabilistic value-based multi-criteria decision analysis (MCDA) method. Probability distributions were used to model random variation and parameter uncertainty in preferences, and parameter uncertainty in clinical outcomes. The posterior value distributions and rank probabilities for each treatment were obtained using Monte-Carlo simulations. The probability of achieving the first rank is the probability that a treatment represents the highest value to patients. We illustrated our methodology for a simplified case on six HIV treatments. Preferences were modeled with normal distributions and clinical outcomes were modeled with beta distributions. The treatment value distributions showed the rank order of treatments according to patients and illustrate the remaining decision uncertainty. This study demonstrated how patient preference data can be used to weigh clinical evidence using MCDA. The model takes into account uncertainty in preferences and clinical outcomes. The model can support decision makers during the aggregation step of the MCDA process and provides a first step toward preference-based personalized medicine, yet requires further testing regarding its appropriate use in real-world settings.
监管机构已经认识到患者参与的必要性,但对于如何将其付诸实践尚无共识。一种方法是正式征求并运用患者偏好来权衡临床结果。本研究的目的是通过应用基于概率值的多标准决策分析(MCDA)方法,展示在偏好和临床结果均不确定的情况下,如何利用患者偏好来权衡临床结果。概率分布用于对偏好中的随机变化和参数不确定性以及临床结果中的参数不确定性进行建模。使用蒙特卡罗模拟获得每种治疗的后验值分布和排序概率。获得第一排名的概率是指一种治疗对患者而言代表最高价值的概率。我们针对六种艾滋病治疗方法的简化案例阐述了我们的方法。偏好采用正态分布建模,临床结果采用贝塔分布建模。治疗价值分布显示了根据患者的治疗排序,并说明了剩余的决策不确定性。本研究展示了如何使用MCDA利用患者偏好数据来权衡临床证据。该模型考虑了偏好和临床结果中的不确定性。该模型可以在MCDA过程的汇总步骤中为决策者提供支持,并朝着基于偏好的个性化医疗迈出了第一步,但仍需要进一步测试其在现实环境中的适当应用。